Log in

ASX:IMCImmuron Stock Price, Forecast & News

0.00 (0.00 %)
(As of 05/13/2020)
Today's Range
Now: A$0.09
50-Day Range
MA: A$0.09
52-Week Range
Now: A$0.09
Volume175,856 shs
Average VolumeN/A
Market Capitalization$15.06 million
P/E RatioN/A
Dividend YieldN/A
Immuron Limited, a biopharmaceutical company, focuses on the research and development of immunomodulatory polyclonal antibodies for the treatment and prevention of various diseases through its oral immunoglobulins platform in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. The company markets Travelan for the prevention of travelers' diarrhea. Its lead product candidate IMM-124E is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease. The company is also developing IMM-529, a clinical stage product for clostridium difficile infections. The company has a research and development collaboration agreement with the Walter Reed Army Institute of Research to develop a vaccine for a form of dysentery; and US Naval Medical Research Center to test the reactivity and therapeutic effectiveness of Travelan against Campylobacter and enterotoxigenic escherichia coli. Immuron Limited was founded in 1994 and is headquartered in Carlton, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.54 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology
Phone61 3 9824 5254



Sales & Book Value

Annual Sales$2.97 million
Cash FlowA$0.03 per share
Book ValueA$0.04 per share



Market Cap$15.06 million
Next Earnings DateN/A
OptionableNot Optionable

Receive IMC News and Ratings via Email

Sign-up to receive the latest news and ratings for IMC and its competitors with MarketBeat's FREE daily newsletter.

Immuron (ASX:IMC) Frequently Asked Questions

How has Immuron's stock been impacted by COVID-19 (Coronavirus)?

Immuron's stock was trading at A$0.11 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IMC stock has decreased by 19.0% and is now trading at A$0.09. View which stocks have been most impacted by Coronavirus.

Has Immuron been receiving favorable news coverage?

News stories about IMC stock have trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Immuron earned a news sentiment score of -1.6 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news aboutImmuron.

Who are some of Immuron's key competitors?

Who are Immuron's key executives?

Immuron's management team includes the following people:
  • Mr. Peter Anastasiou, Exec. Vice Chairman (Age 59)
  • Dr. Jerry Kanellos Ph.D., Chief Operating Officer (Age 58)
  • Dr. Gary S. Jacob, CEO & Director (Age 72)
  • Mr. Phillip Allen Hains, CFO & Company Sec. (Age 60)
  • Mr. David Lyon, Head of Marketing

What is Immuron's stock symbol?

Immuron trades on the ASX under the ticker symbol "IMC."

What is Immuron's stock price today?

One share of IMC stock can currently be purchased for approximately A$0.09.

How big of a company is Immuron?

Immuron has a market capitalization of $15.06 million and generates $2.97 million in revenue each year.

What is Immuron's official website?

The official website for Immuron is www.immuron.com.au.

How can I contact Immuron?

The company can be reached via phone at 61 3 9824 5254.

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.